ASLN vs. CNSP, THAR, MYNZ, SNOA, MTNB, GLTO, MBIO, SNGX, MBRX, and RDHL
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include CNS Pharmaceuticals (CNSP), Tharimmune (THAR), Mainz Biomed (MYNZ), Sonoma Pharmaceuticals (SNOA), Matinas Biopharma (MTNB), Galecto (GLTO), Mustang Bio (MBIO), Soligenix (SNGX), Moleculin Biotech (MBRX), and Redhill Biopharma (RDHL). These companies are all part of the "pharmaceutical products" industry.
ASLAN Pharmaceuticals vs. Its Competitors
ASLAN Pharmaceuticals (NASDAQ:ASLN) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.
58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, CNS Pharmaceuticals had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for CNS Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.75 beat ASLAN Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.
CNS Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CNS Pharmaceuticals' return on equity of -385.41% beat ASLAN Pharmaceuticals' return on equity.
CNS Pharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 2,614.44%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.58, indicating that its share price is 158% more volatile than the S&P 500.
Summary
CNS Pharmaceuticals beats ASLAN Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ASLN) was last updated on 7/5/2025 by MarketBeat.com Staff
